Suggestions
Michael Castagna
Chief Executive Officer, MannKind (NASDAQ: MNKD)
Michael Castagna is the Chief Executive Officer of MannKind Corporation, a biopharmaceutical company focused on developing and commercializing therapeutic products for patients with diseases such as diabetes. Here are some key details about his background and role:
Professional Experience
Castagna became CEO of MannKind Corporation in May 2017, also joining the company's board of directors at that time.1 Prior to becoming CEO, he served as MannKind's Chief Commercial Officer starting in March 2016.2
He brings over 25 years of experience in the healthcare, pharmaceutical, biotech, and specialty pharmacy industries to his role.25 Before joining MannKind, Castagna held leadership positions at other major pharmaceutical companies:
- Vice President at Amgen, where he led global commercial efforts for biosimilar drugs and lifecycle management2
- Executive Director at Bristol-Myers Squibb, co-leading the relaunch of Orencia for rheumatoid arthritis2
Education and Expertise
Castagna holds a Doctor of Pharmacy (Pharm.D.) degree and later obtained an MBA from a top-tier business school.3 This combination of pharmaceutical expertise and business acumen has shaped his career trajectory in the industry.
Leadership at MannKind
As CEO, Castagna has been instrumental in:
- Leading the commercialization efforts for Afrezza, MannKind's inhaled insulin product12
- Guiding the company's strategic direction and growth
- Expanding MannKind's portfolio, including the acquisition of V-Go, a wearable insulin delivery device4
Castagna's leadership style appears to be driven by a mission to help patients and innovate in the pharmaceutical space, continuing the legacy of MannKind's founder, Alfred Mann.34
Highlights
Exciting to be here at the RBC conference! Looking forward to our Fireside chat with Gregory Renza at 4:05!
I want to take a moment to celebrate the incredible journey we have been on at MNKD. Eight years ago today I joined a struggling company with a broken spirit, no pipeline, a failed launch and less than a qtr of cash left. With the unwavering support of our board, Jeffrey Kaplan, Martine Rothblatt, my family and the Mann estate, our leadership team was given the time and flexibility to rebuild our MNKD foundation to keep Al Mann's dream alive.
Despite all the odds against us and a global pandemic, MNKD is now a thriving company with three products on the market, a robust pipeline, and over 400 dedicated employees striving to change lives across the world. We are determined to make a difference in the lives of those affected by diabetes, PAH, ILD, NTM, IPF, and CF.
I am thankful for my family, my health, as well as our employees who make it all happen! I am fortunate and lucky to lead such a passionate, purpose driven team of Mannitarians as we enter into an incredibly exciting future! Together we can all make a difference to change the world #MNKD #DiabetesAwareness #Healthcare #Innovation #CarpeDiem
